Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Zimmer Biomet (NYSE:ZBH) released its quarterly earnings data on Monday. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04, RTT News reports. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company had revenue of $1.91 billion for the quarter, compared to analysts’ expectations of $1.89 billion. During the same quarter in the prior year, the firm earned $1.94 EPS. The business’s revenue was up 1.1% on a year-over-year basis. Zimmer Biomet updated its FY 2025 guidance to 7.900-8.100 EPS.

Zimmer Biomet Price Performance

ZBH opened at $90.34 on Tuesday. The company has a market capitalization of $17.87 billion, a price-to-earnings ratio of 20.30, a PEG ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $105.24 and a 200-day moving average price of $106.42. Zimmer Biomet has a twelve month low of $89.92 and a twelve month high of $122.25.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.06%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.95% of the stock is owned by insiders.

Institutional Trading of Zimmer Biomet

A hedge fund recently bought a new stake in Zimmer Biomet stock. Brighton Jones LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,936 shares of the medical equipment provider’s stock, valued at approximately $204,000. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ZBH shares. BTIG Research restated a “buy” rating on shares of Zimmer Biomet in a report on Monday, April 14th. Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Raymond James reduced their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Truist Financial reissued a “hold” rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.